{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:40:23Z","timestamp":1785577223279,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Domestic Animal Endocrinology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.domaniend.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T17:43:51Z","timestamp":1549820631000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-6425","authenticated-orcid":false,"given":"D.I.","family":"Rendle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9388","authenticated-orcid":false,"given":"G.","family":"Doran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.domaniend.2019.01.008_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0749-0739(02)00018-4","article-title":"Pituitary pars intermedia dysfunction: equine Cushing's disease","volume":"18","author":"Schott","year":"2002","journal-title":"Vet Clin North Am Equine Pract"},{"key":"10.1016\/j.domaniend.2019.01.008_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.2042-3306.2012.00578.x","article-title":"Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses","volume":"45","author":"Mcgowan","year":"2013","journal-title":"Equine Vet J"},{"key":"10.1016\/j.domaniend.2019.01.008_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.2042-3306.2010.00361.x","article-title":"Disease prevalence in geriatric horses in the United Kingdom: veterinary clinical assessment of 200 cases","volume":"44","author":"Ireland","year":"2012","journal-title":"Equine Vet J"},{"key":"10.1016\/j.domaniend.2019.01.008_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cveq.2010.12.007","article-title":"Equine pituitary pars intermedia dysfunction","volume":"27","author":"McFarlane","year":"2011","journal-title":"Vet Clin North Am Equine Pract"},{"key":"10.1016\/j.domaniend.2019.01.008_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejphar.2011.05.050","article-title":"Functional potencies of dopamine agonists and antagonists at human dopamine D2 and D3 receptors","volume":"666","author":"Tadori","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.domaniend.2019.01.008_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0014-2999(98)00896-6","article-title":"Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors","volume":"366","author":"Perachon","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.domaniend.2019.01.008_bib7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1210\/endo-110-4-1430","article-title":"Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests","volume":"110","author":"Orth","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.domaniend.2019.01.008_bib8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM198309223091205","article-title":"Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone","volume":"309","author":"Kleinberg","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.domaniend.2019.01.008_bib9","series-title":"Pharmacokinetics of pergolide in normal mares","author":"Wright","year":"2009"},{"key":"10.1016\/j.domaniend.2019.01.008_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2460\/ajvr.76.2.155","article-title":"Pharmacokinetics of pergolide after intravenous administration to horses","volume":"76","author":"Rendle","year":"2015","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.domaniend.2019.01.008_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvp.12339","article-title":"Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction","volume":"40","author":"McFarlane","year":"2017","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.domaniend.2019.01.008_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2460\/javma.231.3.417","article-title":"Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia","volume":"231","author":"Beech","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.domaniend.2019.01.008_bib13","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.5740\/jaoacint.12-282","article-title":"The analysis of pergolide residues in horse plasma by LC with fluorescence detection","volume":"96","author":"Doran","year":"2013","journal-title":"J AOAC Int"},{"key":"10.1016\/j.domaniend.2019.01.008_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2885.2004.00600.x","article-title":"Plasma terminal half-life","volume":"27","author":"Toutain","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.domaniend.2019.01.008_bib15","series-title":"Basic pharmacokinetics","author":"Jambhekar","year":"2009"},{"key":"10.1016\/j.domaniend.2019.01.008_bib16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2746\/042516402776250333","article-title":"Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide","volume":"34","author":"Perkins","year":"2002","journal-title":"Equine Vet J"},{"key":"10.1016\/j.domaniend.2019.01.008_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/eve.12160","article-title":"Pituitary pars intermediadysfunction: diagnosis and treatment","volume":"26","author":"Durham","year":"2014","journal-title":"Equine Vet Ed"},{"key":"10.1016\/j.domaniend.2019.01.008_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jevs.2008.12.006","article-title":"Correlation of plasma insulin concentration with laminitis score in a field study of equine Cushing's disease and equine metabolic syndrome","volume":"29","author":"Walsh","year":"2009","journal-title":"J Equine Vet Sci"},{"key":"10.1016\/j.domaniend.2019.01.008_bib19","first-page":"742","article-title":"Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease)","volume":"16","author":"Donaldson","year":"2002","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.domaniend.2019.01.008_bib20","first-page":"22","article-title":"The Michigan cushing's project","volume":"47","author":"Schott","year":"2001","journal-title":"AAEP Proceedings"},{"key":"10.1016\/j.domaniend.2019.01.008_bib21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1939-1676.2012.00932.x","article-title":"Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004","volume":"26","author":"Rohrbach","year":"2012","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.domaniend.2019.01.008_bib22","series-title":"Prascend freedom of information summary","first-page":"1","year":"2011"},{"key":"10.1016\/j.domaniend.2019.01.008_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/ENDO:28:1:101","article-title":"Treatment of pituitary tumors: dopamine agonists","volume":"28","author":"Iv\u00e1n","year":"2005","journal-title":"Endocrine"},{"key":"10.1016\/j.domaniend.2019.01.008_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1012836331506","article-title":"Pergolide as primary therapy for macroprolactinomas","volume":"3","author":"Orrego","year":"2000","journal-title":"Pituitary"},{"key":"10.1016\/j.domaniend.2019.01.008_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/evj.12114","article-title":"Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction","volume":"46","author":"Rendle","year":"2014","journal-title":"Equine Vet J"},{"key":"10.1016\/j.domaniend.2019.01.008_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.domaniend.2019.01.008_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1354\/vp.45-1-26","article-title":"Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction","volume":"45","author":"Miller","year":"2008","journal-title":"Vet Pathol"}],"container-title":["Domestic Animal Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0739724019300104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0739724019300104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:51:35Z","timestamp":1760035895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0739724019300104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":27,"alternative-id":["S0739724019300104"],"URL":"https:\/\/doi.org\/10.1016\/j.domaniend.2019.01.008","relation":{},"ISSN":["0739-7240"],"issn-type":[{"value":"0739-7240","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction","name":"articletitle","label":"Article Title"},{"value":"Domestic Animal Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.domaniend.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}